Nanoform Partners with Revio Therapeutics
Nanoform Finland Plc, a medicine performance-enhancing company, announced a partnership with Revio Therapeutics, a specialty pharma company, to co-develop and commercialize GLIORA.
GLIORA is a nano-formulated combination of olaparib (Lynparza®) and temozolomide (Temodar®) as a locally-administered, long-acting, thermo-responsive hydrogel, for the treatment of high-grade glioma.
- Partners: Nanoform Finland Plc and Revio Therapeutics
- Product: GLIORA, a nano-formulated combination of olaparib and temozolomide
- Indication: Treatment of high-grade glioma, a fast-growing and aggressive type of brain tumor
No direct quote available in the given text.
Author's summary: Nanoform partners with Revio Therapeutics to develop GLIORA for glioma treatment.
More News
- Community pharmacies and BioPharma: Advancing whole-patient care together
- New ‘Pay One, Stay Two’ parking deal to boost Waverley town centres
- Abbott Told to Provide Prescribing Details, Supporting Data for Triamcinolone Hexacetonide Pre-Filled Syringe
- Which Non-League sides will take part in the Isuzu FA Trophy Second Round Proper? - The Non-League Football Paper
- MMJ BioPharma Cultivation: EXPOSÉ: DEA's Marijuana Licensing Scheme Exposed - MMJ BioPharma's Case Reveals DEA Contradiction Blocking FDA Approved Cannabis Medicine
- Guildford Dragon NEWS
- This ‘minor’ bird flu strain has potential to spark human pandemic
- Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
- Kymera Therapeutics, Inc.: Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting
- Tapering Methotrexate Is Feasible in Stable RA With Careful Monitoring